Yeast Surface-Displayed H5N1 Avian Influenza Vaccines

Highly pathogenic H5N1 avian influenza viruses pose a pandemic threat to human health. A rapid vaccine production against fast outbreak is desired. We report, herein, a paradigm-shift influenza vaccine technology by presenting H5N1 hemagglutinin (HA) to the surface of yeast. We demonstrated, for the...

Full description

Saved in:
Bibliographic Details
Main Authors: Han Lei, Sha Jin, Erik Karlsson, Stacey Schultz-Cherry, Kaiming Ye
Format: Article
Language:English
Published: Wiley 2016-01-01
Series:Journal of Immunology Research
Online Access:http://dx.doi.org/10.1155/2016/4131324
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1850167232768770048
author Han Lei
Sha Jin
Erik Karlsson
Stacey Schultz-Cherry
Kaiming Ye
author_facet Han Lei
Sha Jin
Erik Karlsson
Stacey Schultz-Cherry
Kaiming Ye
author_sort Han Lei
collection DOAJ
description Highly pathogenic H5N1 avian influenza viruses pose a pandemic threat to human health. A rapid vaccine production against fast outbreak is desired. We report, herein, a paradigm-shift influenza vaccine technology by presenting H5N1 hemagglutinin (HA) to the surface of yeast. We demonstrated, for the first time, that the HA surface-presented yeast can be used as influenza vaccines to elicit both humoral and cell-mediated immunity in mice. The HI titer of antisera reached up to 128 in vaccinated mice. A high level of H5N1 HA-specific IgG1 and IgG2a antibody production was detected after boost immunization. Furthermore, we demonstrated that the yeast surface-displayed HA preserves its antigenic sites. It preferentially binds to both avian- and human-type receptors. In addition, the vaccine exhibited high cross-reactivity to both homologous and heterologous H5N1 viruses. A high level production of anti-HA antibodies was detected in the mice five months after vaccination. Finally, our animal experimental results indicated that the yeast vaccine offered complete protection of mice from lethal H5N1 virus challenge. No severe side effect of yeast vaccines was noted in animal studies. This new technology allows for rapid and large-scale production of influenza vaccines for prepandemic preparation.
format Article
id doaj-art-e2b59236dcab4bbdbcf445f783a30975
institution OA Journals
issn 2314-8861
2314-7156
language English
publishDate 2016-01-01
publisher Wiley
record_format Article
series Journal of Immunology Research
spelling doaj-art-e2b59236dcab4bbdbcf445f783a309752025-08-20T02:21:14ZengWileyJournal of Immunology Research2314-88612314-71562016-01-01201610.1155/2016/41313244131324Yeast Surface-Displayed H5N1 Avian Influenza VaccinesHan Lei0Sha Jin1Erik Karlsson2Stacey Schultz-Cherry3Kaiming Ye4Department of Biomedical Engineering, Watson School of Engineering and Applied Sciences, Binghamton University, State University of New York (SUNY), Binghamton, NY 13902, USADepartment of Biomedical Engineering, Watson School of Engineering and Applied Sciences, Binghamton University, State University of New York (SUNY), Binghamton, NY 13902, USADepartment of Infectious Diseases, St. Jude Children’s Research Hospital, Memphis, TN 38105, USADepartment of Infectious Diseases, St. Jude Children’s Research Hospital, Memphis, TN 38105, USADepartment of Biomedical Engineering, Watson School of Engineering and Applied Sciences, Binghamton University, State University of New York (SUNY), Binghamton, NY 13902, USAHighly pathogenic H5N1 avian influenza viruses pose a pandemic threat to human health. A rapid vaccine production against fast outbreak is desired. We report, herein, a paradigm-shift influenza vaccine technology by presenting H5N1 hemagglutinin (HA) to the surface of yeast. We demonstrated, for the first time, that the HA surface-presented yeast can be used as influenza vaccines to elicit both humoral and cell-mediated immunity in mice. The HI titer of antisera reached up to 128 in vaccinated mice. A high level of H5N1 HA-specific IgG1 and IgG2a antibody production was detected after boost immunization. Furthermore, we demonstrated that the yeast surface-displayed HA preserves its antigenic sites. It preferentially binds to both avian- and human-type receptors. In addition, the vaccine exhibited high cross-reactivity to both homologous and heterologous H5N1 viruses. A high level production of anti-HA antibodies was detected in the mice five months after vaccination. Finally, our animal experimental results indicated that the yeast vaccine offered complete protection of mice from lethal H5N1 virus challenge. No severe side effect of yeast vaccines was noted in animal studies. This new technology allows for rapid and large-scale production of influenza vaccines for prepandemic preparation.http://dx.doi.org/10.1155/2016/4131324
spellingShingle Han Lei
Sha Jin
Erik Karlsson
Stacey Schultz-Cherry
Kaiming Ye
Yeast Surface-Displayed H5N1 Avian Influenza Vaccines
Journal of Immunology Research
title Yeast Surface-Displayed H5N1 Avian Influenza Vaccines
title_full Yeast Surface-Displayed H5N1 Avian Influenza Vaccines
title_fullStr Yeast Surface-Displayed H5N1 Avian Influenza Vaccines
title_full_unstemmed Yeast Surface-Displayed H5N1 Avian Influenza Vaccines
title_short Yeast Surface-Displayed H5N1 Avian Influenza Vaccines
title_sort yeast surface displayed h5n1 avian influenza vaccines
url http://dx.doi.org/10.1155/2016/4131324
work_keys_str_mv AT hanlei yeastsurfacedisplayedh5n1avianinfluenzavaccines
AT shajin yeastsurfacedisplayedh5n1avianinfluenzavaccines
AT erikkarlsson yeastsurfacedisplayedh5n1avianinfluenzavaccines
AT staceyschultzcherry yeastsurfacedisplayedh5n1avianinfluenzavaccines
AT kaimingye yeastsurfacedisplayedh5n1avianinfluenzavaccines